In CRC, METTL3 promotes VM indirectly by targeting Eph receptor A2 (EphA2) and VEGFA, enhancing their stability through IGF2BP2 and IGF2BP3, respectively [69]. The gene discussed is VEGFA; the disease is colorectal carcinoma.